These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 22704456)
1. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. Kotera J; Mochida H; Inoue H; Noto T; Fujishige K; Sasaki T; Kobayashi T; Kojima K; Yee S; Yamada Y; Kikkawa K; Omori K J Urol; 2012 Aug; 188(2):668-74. PubMed ID: 22704456 [TBL] [Abstract][Full Text] [Related]
2. Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs. Mochida H; Yano K; Inoue H; Yee S; Noto T; Kikkawa K J Urol; 2013 Aug; 190(2):799-806. PubMed ID: 23321580 [TBL] [Abstract][Full Text] [Related]
3. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639 [TBL] [Abstract][Full Text] [Related]
4. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects. Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324 [TBL] [Abstract][Full Text] [Related]
5. The selectivity and potency of the new PDE5 inhibitor TPN729MA. Wang Z; Zhu D; Yang X; Li J; Jiang X; Tian G; Terrett NK; Jin J; Wu H; He Q; Yang B; Shen J J Sex Med; 2013 Nov; 10(11):2790-7. PubMed ID: 23937247 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of vardenafil and sildenafil in facilitating penile erection in an animal model. Choi S; O'Connell L; Min K; Kim NN; Munarriz R; Goldstein I; Bischoff E; Traish AM J Androl; 2002; 23(3):332-7. PubMed ID: 12002434 [TBL] [Abstract][Full Text] [Related]
7. T-0156, a novel phosphodiesterase type 5 inhibitor, and sildenafil have different pharmacological effects on penile tumescence and electroretinogram in dogs. Mochida H; Noto T; Inoue H; Yano K; Kikkawa K Eur J Pharmacol; 2004 Feb; 485(1-3):283-8. PubMed ID: 14757152 [TBL] [Abstract][Full Text] [Related]
8. Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs. Noto T; Inoue H; Ikeo T; Kikkawa K J Pharmacol Exp Ther; 2000 Sep; 294(3):870-5. PubMed ID: 10945835 [TBL] [Abstract][Full Text] [Related]
9. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. Toque HA; Priviero FB; Teixeira CE; Claudino MA; Baracat JS; Fregonesi A; De Nucci G; Antunes E Urology; 2009 Jul; 74(1):216-21. PubMed ID: 19371941 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice. Ali ST Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424 [TBL] [Abstract][Full Text] [Related]
11. [Pharmacodynamics and pharmacokinetics of vardenafil in patients with erectile dysfunction]. Jin J; Guo Y Zhonghua Nan Ke Xue; 2004 Sep; 10(9):711-6. PubMed ID: 15497717 [TBL] [Abstract][Full Text] [Related]
12. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Limin M; Johnsen N; Hellstrom WJ Expert Opin Investig Drugs; 2010 Nov; 19(11):1427-37. PubMed ID: 20939743 [TBL] [Abstract][Full Text] [Related]
13. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes. Rosen RC; McKenna KE Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729 [TBL] [Abstract][Full Text] [Related]
14. A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection. Bischoff E; Schneider K Int J Impot Res; 2001 Aug; 13(4):230-5. PubMed ID: 11494080 [TBL] [Abstract][Full Text] [Related]
15. Relationship between nocturnal penile tumescence parameters, International Index of Erectile Function symptom scores and sildenafil responses1This paper was presented at the 6th Congress of the International Society of Sexual and Impotence Research, Buenos Aires, Argentina, 17-21 October 2004. Murad Başar M; Tuğlu D; Yilmaz E; Başar H; Batislam E Scand J Urol Nephrol; 2006; 40(6):506-10. PubMed ID: 17130103 [TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit. Firoozi F; Longhurst PA; White MD BJU Int; 2005 Jul; 96(1):164-8. PubMed ID: 15963142 [TBL] [Abstract][Full Text] [Related]
17. [Effect of sildenafil on nocturnal penile tumescence]. Chen ZY; Chen YH; Zhu HB; He YH; Zhang L; Yang SK Zhonghua Nan Ke Xue; 2006 Aug; 12(8):706-7, 711. PubMed ID: 16970159 [TBL] [Abstract][Full Text] [Related]
18. Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum. Hallén K; Wiklund NP; Gustafsson LE Br J Pharmacol; 2007 Feb; 150(3):353-60. PubMed ID: 17179943 [TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action. Sanna F; Succu S; Boi A; Melis MR; Argiolas A J Sex Med; 2009 Oct; 6(10):2680-9. PubMed ID: 19678884 [TBL] [Abstract][Full Text] [Related]
20. Pharmacology of phosphodiesterase 5 inhibitors. Carrier S Can J Urol; 2003 Feb; 10 Suppl 1():12-6. PubMed ID: 12625845 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]